ArticleJCO precision oncology2026
Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.
Rika Terashima, Judy Fan, Fatma Gunturkun, Grant Nieda, Xiaomei Fan, Emily M Rodriguez, Annabel X Tan, Stefan Thottunkal, Maggie Shaw, Chloe C Su and 14 more
Abstract read
In one paragraphArticle in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
Rika TerashimaDepartment of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.ORCID 0000-0002-3650-9269 Judy FanDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0001-7300-1563 Grant NiedaQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA.
Xiaomei FanDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.
Emily M RodriguezQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA.
Stefan ThottunkalDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.
Maggie ShawQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA.
Aparajita KhanDepartment of Computer Science and Engineering, Indian Institute of Technology (BHU) Varanasi, Varanasi, India.ORCID 0000-0003-0415-9070 Ingrid LuoQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA.
Mina SatoyoshiTechnology and Digital Solutions (TDS), Research Technology, and Research Data Services, Stanford Health Care and Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-3068-4020 Archana BhatTechnology and Digital Solutions (TDS), Research Technology, and Research Data Services, Stanford Health Care and Stanford University School of Medicine, Stanford, CA.
Solomon M HenryTechnology and Digital Solutions (TDS), Research Technology, and Research Data Services, Stanford Health Care and Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-1591-1897 Timothy J Ellis-CaleoDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-3217-8335 Michelle OddenDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-5974-3648 Allison W KurianDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-6175-9470 Joel W NealDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-3119-9334 Heather A WakeleeDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-1136-980X Funding
Integrating Multiple Electronic Health Records Systems to Improve Lung Cancer OutcomesR01CA282793 · NCI · STANFORD UNIVERSITY · PI Summer S Han · 2023 to 2026
$2.6MHSRD VA IK2 HX003949NCI NIH HHS R01 CA282793
6 · The paper itselfAbstract
purposeAs treatment options for advanced non-small cell lung cancer (NSCLC) evolve, biomarkers are needed to guide therapy selection while balancing efficacy and toxicity. Although tumor burden is a promising candidate, its prognostic role in guiding epidermal growth factor receptor (EGFR)-targeted kinase inhibitor (TKI) therapies remains understudied in real-world settings.
methodsWe identified patients with de novo stage IV
resultsOf 312 patients, bone metastasis (hazard ratio (HR)
conclusionTumor burden may serve as a prognostic biomarker in advanced NSCLC receiving EGFR-TKIs. These findings raise the hypothesis that durable survival in low-burden patients may be achievable with monotherapy, potentially sparing unnecessary toxicity from combination regimens. This warrants prospective validation comparing monotherapy versus combination strategies.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsTumor BurdenAgedBiomarkers, TumorErbB ReceptorsFemaleHumansIndolesMaleMiddle AgedPrognosisPyrimidinesBiomarkers, TumorEGFR protein, humanErbB ReceptorsIndolesProtein Kinase InhibitorsPyrimidines
Identifiers
PMID41955549
PMCPMC13086115
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390